Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
暂无分享,去创建一个
Peter T. Lansbury | Jean-Christophe Rochet | P. Lansbury | J. Rochet | K. Conway | R. Bieganski | Kelly A. Conway | Robert M. Bieganski
[1] S Fahn,et al. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. , 1999, Archives of neurology.
[2] W. Bender,et al. A Drosophila model of Parkinson's disease , 2000, Nature.
[3] Y. Agid. Levodopa: Is toxicity a myth? , 1998, Neurology.
[4] M. Zigmond,et al. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[5] T. Dawson. New Animal Models for Parkinson's Disease , 2000, Cell.
[6] P. Lansbury,et al. Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? , 2000, Nature Cell Biology.
[7] T. Osawa,et al. Immunochemical detection of protein dityrosine in atherosclerotic lesion of apo-E-deficient mice using a novel monoclonal antibody. , 2000, Biochemical and biophysical research communications.
[8] D. Kuhn,et al. Dopamine Inactivates Tryptophan Hydroxylase and Forms a Redox-Cycling Quinoprotein: Possible Endogenous Toxin to Serotonin Neurons , 1998, The Journal of Neuroscience.
[9] P. Lansbury,et al. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. , 2000, Biochemistry.
[10] P. Lansbury,et al. Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? , 1993, Cell.
[11] J. Waite,et al. Cross-linking in adhesive quinoproteins: studies with model decapeptides. , 2000, Biochemistry.